Reassuringly, the conclusions extracted from studies around the world that include considerable follow-up data indicate there is no clear evidence from clinical practice that GH treatment has a causal relationship with tumor occurrence or recurrence [52,53]. The gene discussed is GH1; the disease is neoplasm.